DocGo DCGO 深 滬
等待開盤 04-03 09:30:00 美东时间
0.57
+0.002
+0.26%
華盛通- 最 高0.5771
- 今 開0.553
- 成交量 257.06万股
- 最 低 0.553
- 昨 收 0.5685
- 總市值 5628.76万
- 52周最高 2.51
- 市盈率 靜 --
- 換手率 2.60%
- 52周最低 0.553
- 委 比 -13.90%
- 總股本 9875.03万
- 歷史最高 11.41
- 量 比 2.22
- 振 幅 4.24%
- 歷史最低 0.553
- 每 手 1
- 風險率 0.49%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高240美元，潜在涨幅53%！ARM获多家大行上调目标价；Braze 评级上演 “两极反转”，小摩、巴克莱上调，高盛、花旗下调
今日重点评级关注：HC Wainwright & Co.：维持OCUGEN"买入"评级，目标价从7美元升至10美元；HC Wainwright & Co.：维持Maze Therapeutics"买入"评级，目标价从60美元升至110美元
03-26 11:41
Canaccord Genuity Maintains Hold on DocGo, Lowers Price Target to $1
Canaccord Genuity analyst Richard Close maintains DocGo (NASDAQ:DCGO) with a Hold and lowers the price target from $1.5 to $1.
03-25 21:55
美股大行评级 | 摩根大通上调哔哩哔哩至"超配"，目标价从27美元升至35美元；Rhythm遭花旗、大摩等多家机构下调目标价
今日重点评级关注：韦德布什：维持Black Diamond Therapeutic"跑赢大市"评级，目标价从13美元升至14美元；花旗：维持Olema Pharmaceuticals"买入"评级，目标价从60美元升至62美元
03-18 10:48
Needham Reiterates Buy on DocGo, Maintains $3 Price Target
Needham analyst Ryan MacDonald reiterates DocGo (NASDAQ:DCGO) with a Buy and maintains $3 price target.
03-17 19:31
电话会总结 ｜ DocGo(DCGO)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据DocGo业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - Q4 2025总营收7,490万美元，同比下降38%（2024年Q4为1.208亿美元） - 全年2025营收3.222亿美元，同比大幅下降47.8%（2024年为6.166亿美元） - 营收下降完全归因于移民相关项目的结束，剔除移民业务后Q4同比增长11% **分业务营收：** - 医疗运输服务：Q4营收5,020万美元，同比增长2.2%（2024年Q4为4,910万美元） - 移动医疗：Q4营收2,480万美元，同比下降65.5%（2024年Q4为7
03-17 12:03
DocGo shares are trading higher after the company reported better-than-expected Q4 sales results and issued FY26 sales guidance with its midpoint above estimates.
DocGo shares are trading higher after the company reported better-than-expected...
03-17 04:26
DocGo Sees FY2026 Sales $290.000M-$310.000M vs $291.357M Est
DocGo (NASDAQ:DCGO) sees FY2026 sales of $290.000 million-$310.000 million vs $291.357 million analyst estimate.
03-17 04:08
DocGo Q4 EPS $(1.37) Misses $(0.13) Estimate, Sales $74.936M Beat $70.355M Estimate
DocGo (NASDAQ:DCGO) reported quarterly losses of $(1.37) per share which missed the analyst consensus estimate of $(0.13) by 937.88 percent. This is a 3525 percent decrease over earnings of $0.04 per share from the same
03-17 04:08
Earnings Scheduled For March 16, 2026
Companies Reporting Before The Bell • CytomX Therapeutics (NASDAQ:CTMX) is expe...
03-16 19:11
DocGo's Virtual Care Division, SteadyMD, Undertakes Immediate Expansion Of Clinical Workforce, With Plans To Increase Clinical Staff By Up To 50% Over Coming Weeks
SteadyMD to Grow Clinical Staff by Up To 50% to Support Customer Base That Includes Multiple Fortune 10 BrandsDocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled mobile health
01-27 20:39
